Basic Information
Elonva Solution for Injection 100mcg/0.5ml
INJECTION, SOLUTION
Regulatory Information
SIN13939P
March 31, 2011
Prescription Only
Therapeutic
SUBCUTANEOUS
August 10, 2023
May 30, 2025
XG03GA09
Company Information
Active Ingredients
Strength: 0.100mg
Detailed Information
Contraindications
**4.3 Contraindications** - Hypersensitivity to the active substance or to any of the excipients. - Tumors of the ovary, breast, uterus, pituitary or hypothalamus. - Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause. - Primary ovarian failure. - Ovarian cysts or enlarged ovaries. - Fibroid tumors of the uterus incompatible with pregnancy. - Malformations of the reproductive organs incompatible with pregnancy. - Pregnancy (see section 4.6 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) - Risk factors of OHSS - A history of Ovarian Hyperstimulation Syndrome (OHSS). - A previous COS cycle that resulted in more than 30 follicles ≥ 11 mm measured by ultrasound examination. - A basal antral follicle count > 20. - Polycystic ovarian syndrome (PCOS).
Indication Information
**4.1 Therapeutic indications** Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.